Allurion Technologies Inc. (NYSE:ALUR – Free Report) – Research analysts at Chardan Capital upped their FY2024 earnings per share (EPS) estimates for Allurion Technologies in a research report issued on Sunday, January 12th. Chardan Capital analyst K. Nakae now forecasts that the company will post earnings per share of ($7.63) for the year, up from their previous forecast of ($7.75). Chardan Capital currently has a “Neutral” rating on the stock. The consensus estimate for Allurion Technologies’ current full-year earnings is ($0.41) per share. Chardan Capital also issued estimates for Allurion Technologies’ FY2025 earnings at ($4.82) EPS.
Separately, TD Cowen began coverage on shares of Allurion Technologies in a report on Wednesday, October 2nd. They issued a “buy” rating and a $50.00 target price for the company. One analyst has rated the stock with a hold rating, three have assigned a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the company currently has an average rating of “Buy” and a consensus price target of $71.88.
Allurion Technologies Trading Up 13.8 %
Shares of ALUR opened at $3.57 on Wednesday. Allurion Technologies has a 1-year low of $2.72 and a 1-year high of $98.75. The firm has a fifty day simple moving average of $9.66 and a two-hundred day simple moving average of $15.79. The firm has a market cap of $230.06 million, a PE ratio of -7.45 and a beta of -0.56.
Hedge Funds Weigh In On Allurion Technologies
An institutional investor recently bought a new position in Allurion Technologies stock. CVI Holdings LLC purchased a new stake in Allurion Technologies Inc. (NYSE:ALUR – Free Report) during the second quarter, according to its most recent Form 13F filing with the SEC. The fund purchased 521,440 shares of the company’s stock, valued at approximately $520,000. Allurion Technologies accounts for about 0.5% of CVI Holdings LLC’s portfolio, making the stock its 28th largest position. CVI Holdings LLC owned about 1.09% of Allurion Technologies as of its most recent filing with the SEC. 21.39% of the stock is owned by hedge funds and other institutional investors.
Allurion Technologies Company Profile
Allurion Technologies Inc focuses on ending obesity with a weight loss platform to treat people who are overweight. Its platform, the Allurion Program, features swallowable and procedure-less intragastric balloon for weight loss (the Allurion Balloon), as well as offers access to AI-powered remote patient monitoring tools, a proprietary behavior change program, secure messaging, and video telehealth that are delivered by the Allurion Virtual Care Suite.
Featured Stories
- Five stocks we like better than Allurion Technologies
- What is a support level?
- 4 Social Media Stocks Set to Gain as TikTok Ban Looms
- Best Stocks Under $10.00
- How Do Stock Buybacks Affect Shareholders?
- Stock Average Calculator
- JPMorgan Chase & Co. Stock Can Hit $300 This Year
Receive News & Ratings for Allurion Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allurion Technologies and related companies with MarketBeat.com's FREE daily email newsletter.